Lucile Fossier

Lucile Fossier

Auto-generated profile, based on publicly available information

Lucile Fossier

Department of Physiology and Cellular Biophysics, Columbia University, New York, NY 10032, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in Journal of Biological Chemistry
Verified
Journal Article
Open access
KWKatharine M. Wright
Katharine M. Wright
SNSara Nathan
Sara Nathan
HJHanjie Jiang
Hanjie Jiang
WXWendy Xia
Wendy Xia
HKHyoJeon Kim
HyoJeon Kim
SGSandra B. Gabelli
Sandra B. Gabelli
NEDD4L is a HECT-type E3 ligase that catalyzes the addition of ubiquitin to intracellular substrates such as the cardiac voltage-gated sodium channel, NaV1.5. The intramolecular interactions of NEDD4L regulate its enzymatic activity which is essential for proteostasis. For NaV1.5, this process is critical as alterations in Na+ current is involved in cardiac diseases including arrhythmias and heart failure. In this study, we perform extensive biochemical and functional analyses that implicate the C2 domain and the first WW-linker (1,2-linker) in the autoregulatory mechanism of NEDD4L. Through in vitro and electrophysiological experiments, the NEDD4L 1,2-linker was determined to be important in substrate ubiquitination of NaV1.5. We establish the preferred sites of ubiquitination of NEDD4L to be in the second WW-linker (2,3-linker). Interestingly, NEDD4L ubiquitinates the cytoplasmic linker between the first and second transmembrane domains of the channel (DI-DII) of NaV1.5. Moreover, we design a genetically encoded modulator of Nav1.5 that achieves Na+ current reduction using the NEDD4L HECT domain as cargo of a NaV1.5-binding nanobody. These investigations elucidate the mechanisms regulating the NEDD4 family and furnish a new molecular framework for understanding NaV1.5 ubiquitination.

26 May 2026 in Circulation Research
Verified
Journal Article
Open access
BHBence Hegyi
Bence Hegyi
PAPaweorn Angsutararux
Paweorn Angsutararux
NCNourdine Chakouri
Nourdine Chakouri
RMRyan W. Mahling
Ryan W. Mahling
LFLucile Fossier
Lucile Fossier
DBDonald Bers
Donald Bers
BACKGROUND: Enhanced late Na + current (I Na,L ) in heart failure (HF) contributes to cardiomyocyte proarrhythmia. In addition to CaMKII (Ca 2+ /calmodulin-dependent protein kinase II), FGF (fibroblast growth factor) homologous factors 1–4 (FHF1–4) also modulate I Na,L , and targeting these pathways may provide benefits in HF. METHODS: Reverse-transcriptase quantitative polymerase chain reaction analysis of cardiac Na + channel and FHF splice isoforms was performed in human arrhythmogenic HF with reduced ejection fraction (HFrEF) and in translational animal models of HFrEF and HF with preserved ejection fraction. We tested the effects of an FixR (FHF inhibiting x region) on cardiomyocyte I Na,L and electrophysiology in rabbit HFrEF and murine models of HFrEF and HF with preserved ejection fraction. We also tested the in vivo electrophysiological effects of FixR via adenoviral delivery in transgenic mice with cardiomyocyte-specific overexpression of CaMKIIδ C . RESULTS: Expression of key FHF long isoforms (FHF1 A in humans, FHF2 S in rabbits, and FHF2 VY in mice) that have inhibitory effects on I Na,L was reduced in human, rabbit, and murine failing hearts. I Na,L was markedly enhanced in both HFrEF and HF with preserved ejection fraction, and the FixR cell-penetrating peptide significantly reduced pathological I Na,L in both forms of HF. FixR had no effect on transient peak Na + current, L-type Ca 2+ current, or major K + currents in rabbit ventricular myocytes. FixR markedly attenuated proarrhythmogenic action potential changes (increased action potential duration, short-term variability, and alternans susceptibility) and delayed afterdepolarizations in both rabbit and murine failing cardiomyocytes. These cellular antiarrhythmic effects were mimicked by the selective I Na,L inhibitor GS967 and the CaMKII inhibitor AIP (autocamtide-2 inhibitory peptide). FixR also attenuated QT prolongation and in vivo arrhythmia susceptibility in transgenic mice with cardiomyocyte-specific overexpression of CaMKIIδ C . CONCLUSIONS: In HF, I Na,L is increased, and FHF splice isoform expression is altered, allowing a novel mechanism to therapeutically target I Na,L . FixR, an FHF1 A -derived peptide, is a potent and selective I Na,L inhibitor and has antiarrhythmic properties in both HFrEF and HF with preserved ejection fraction cardiomyocytes.

28 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRyan Mahling
Ryan Mahling
BHBence Hegyi
Bence Hegyi
ECErin R. Cullen
Erin R. Cullen
TCTimothy M. Cho
Timothy M. Cho
ARAaron R. Rodriques
Aaron R. Rodriques
MBManu Ben-Johny
Manu Ben-Johny
Summary: Ion channels orchestrate electrical signaling in excitable cells. In nature, ion channel function is customized by modulatory proteins that have evolved to fulfill distinct physiological needs. Yet, engineering synthetic modulators that precisely tune ion channel function is challenging. One example involves the voltage-gated sodium (Na V ) channel that initiates the action potential, and whose dysfunction amplifies late/persistent sodium current ( I NaL ), a commonality that underlies various human diseases including cardiac arrhythmias and epilepsy. Here, using a computational protein design platform, we engineered a de novo peptide modulator, ELIXIR, that binds Na V channels with submicromolar affinity. Functional analysis revealed an unexpected selectivity in inhibiting ‘pathogenic’ I NaL and confirmed its effectiveness in reversing Na V dysfunction linked to both cardiac arrhythmias and epilepsy in cellular and murine models. These findings exemplify the efficacy of de novo protein design for engineering synthetic ion channel modulators and sets the stage for rational design of future therapeutic approaches.

14 June 2023 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
LFLucile Fossier
Lucile Fossier
MBManu Ben-Johny
Manu Ben-Johny

9 October 2026 in Science Advances
Verified
Journal Article
Closed access
LFLucile Fossier
Lucile Fossier
MYMarc Yehya
Marc Yehya
RZRichard Z. Zhuang
Richard Z. Zhuang
SSSri Karthika Shanmugam
Sri Karthika Shanmugam
RMRyan Mahling
Ryan Mahling
MBManu Ben-Johny
Manu Ben-Johny
Despite their emerging prominence, ion channelopathies have remained challenging to correct, as ion channel dysfunction linked to disease is multifaceted, involving changes in activity and/or localization. Yet, current corrective strategies typically focus on restoring only one aspect leading to incomplete efficacy. Here, focusing on the voltage-gated sodium channel, Na V 1.5, whose dysfunction is linked to life-threatening cardiac arrhythmias, we develop a genetically encoded bifunctional actuator as a proof-of-concept molecular strategy to reverse pathophysiological changes in channel function. Specifically, we engineer a high affinity nanobody targeting Na V 1.5 with two moieties: (i) a peptide that restores proper inactivation and (ii) a linkage-specific deubiquitinase that promotes surface-membrane localization. Functional validation in heterologous systems and in human and mouse cardiomyocytes demonstrated restoration of Na V 1.5 trafficking and/or gating. In all, this approach shows promise for reversing molecular deficits observed with Na V channelopathies and provides a framework to engineer multifunctional modulators targeting ion channelopathies.